ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - acetylsalicylic acid - טבליות עם ציפוי אנטרי - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

ישראל - עברית - Ministry of Health

dexcel ltd, israel - acetylsalicylic acid - טבליות עם ציפוי אנטרי - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

ישראל - עברית - Ministry of Health

gramse intrnational natural products limited partnership, israel - acetylsalicylic acid - טבליה - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - for inhibition of platelet aggregation

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - eptifibatide - תמיסה לאינפוזיה - eptifibatide 0.75 mg/ml - eptifibatide - eptifibatide - integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). integrilin is intended for use with aspirin and heparin.

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - eptifibatide - תמיסה להזרקה - eptifibatide 2 mg/ml - eptifibatide - eptifibatide - integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). integrilin is intended for use with aspirin and heparin.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - eptifibatide 2 mg/ml - solution for injection - eptifibatide - eptifibatide teva is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. eptifibatide is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty directional atheretomy transluminal extraction catheter atherectomy rotational ablation angioplasty or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death myorardial infarction need for urgent intervention). eptifibatide is intended for use with aspirin and heparin.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - tirofiban as hydrochloride monohydrate - תמיסה לאינפוזיה - tirofiban as hydrochloride monohydrate 0.05 mg/ml - tirofiban - tirofiban - aggrastat in combination with heparin, is indicated for patients with unstable angina or non-q-wave myocardial infarction to prevent cardiac ischemic events and is also indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing ptca or atherectomy. in this setting, aggrastat has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - tirofiban as hydrochloride monohydrate 0.25 mg/ml - solution for infusion - tirofiban - aggrastat in combination with heparin, is indicated for patients with unstable angina or non-q-wave myocardial infarction to prevent cardiac ischemic events and is also indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing ptca or atherectomy. in this setting, aggrastat has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure.

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob